Medincell Halts Share Trading on Euronext Paris Amid Pending Disclosure

  • Medincell requested a temporary suspension of its shares on Euronext Paris starting October 9, 2026, pending a press release.
  • The company's BEPO® technology is licensed to Teva as SteadyTeq™ for long-acting injectable treatments.
  • Risperidone LAI (UZEDY®) received FDA approval for schizophrenia in April 2023 and Bipolar I Disorder in October 2025.
  • Olanzapine LAI NDA was submitted by Teva in December 2025, with FDA acceptance in February 2026 and EMA acceptance in May 2026.

Medincell’s trading halt underscores the volatility inherent in biotech stocks ahead of material disclosures. The company’s strategic focus on long-acting injectables aligns with industry trends toward improved patient adherence and reduced environmental impact. Success hinges on regulatory approvals and Teva’s commercial execution of licensed products.

Regulatory Milestones
The pace at which Olanzapine LAI advances through FDA and EMA approvals will determine commercialization timelines.
Market Reaction
How investors interpret the trading suspension and pending disclosure will impact Medincell’s stock volatility.
Pipeline Execution
Whether Medincell can sustain its clinical pipeline momentum amid governance shifts.